| Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation N Chen, W Fang, J Zhan, S Hong, Y Tang, S Kang, Y Zhang, X He, T Zhou, ... Journal of Thoracic Oncology 10 (6), 910-923, 2015 | 665 | 2015 |
| Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial L Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia, P Peng, X Wu, Q Lin, X Xi, ... The Lancet 388 (10054), 1883-1892, 2016 | 490 | 2016 |
| Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials W Fang, Y Yang, Y Ma, S Hong, L Lin, X He, J Xiong, P Li, H Zhao, ... The Lancet Oncology 19 (10), 1338-1350, 2018 | 430 | 2018 |
| EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy W Fang, J Zhang, S Hong, J Zhan, N Chen, T Qin, Y Tang, Y Zhang, ... Oncotarget 5 (23), 12189, 2014 | 406 | 2014 |
| The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs Y Tang, W Fang, Y Zhang, S Hong, S Kang, Y Yan, N Chen, J Zhan, X He, ... Oncotarget 6 (16), 14209, 2015 | 253 | 2015 |
| KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma N Chen, W Fang, Z Lin, P Peng, J Wang, J Zhan, S Hong, J Huang, L Liu, ... Cancer Immunology, Immunotherapy 66, 1175-1187, 2017 | 252 | 2017 |
| Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small … Y Zhang, J Sheng, S Kang, W Fang, Y Yan, Z Hu, S Hong, X Wu, T Qin, ... PloS one 9 (9), e107161, 2014 | 191 | 2014 |
| Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer T Zhou, J Zhan, S Hong, Z Hu, W Fang, T Qin, Y Ma, Y Yang, X He, ... Scientific reports 5 (1), 10481, 2015 | 180 | 2015 |
| Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non–small cell … S Hong, F Gao, S Fu, Y Wang, W Fang, Y Huang, L Zhang JAMA oncology 4 (5), 739-742, 2018 | 163 | 2018 |
| Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer W Fang, Y Ma, JC Yin, S Hong, H Zhou, A Wang, F Wang, H Bao, X Wu, ... Clinical Cancer Research 25 (16), 5015-5026, 2019 | 155 | 2019 |
| Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition X Zhang, Y Zhou, C Chen, W Fang, X Cai, X Zhang, M Zhao, B Zhang, ... Journal for immunotherapy of cancer 7 (1), 322, 2019 | 149 | 2019 |
| Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma J Zhang, W Fang, T Qin, Y Yang, S Hong, W Liang, Y Ma, H Zhao, ... Medical oncology 32, 1-6, 2015 | 137 | 2015 |
| Up-regulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs … S Hong, N Chen, W Fang, J Zhan, Q Liu, S Kang, X He, L Liu, T Zhou, ... OncoImmunology 5 (3), 00-00, 2015 | 134 | 2015 |
| EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer W Fang, Y Huang, S Hong, Z Zhang, M Wang, J Gan, W Wang, H Guo, ... BMC cancer 19, 1-9, 2019 | 130 | 2019 |
| The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients S Hong, T Zhou, W Fang, C Xue, Z Hu, T Qin, Y Tang, Y Chen, Y Ma, ... Tumor Biology 36, 3389-3397, 2015 | 123 | 2015 |
| Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta … Y Zhou, C Chen, X Zhang, S Fu, C Xue, Y Ma, W Fang, Y Yang, X Hou, ... Journal for immunotherapy of cancer 6, 1-11, 2018 | 96 | 2018 |
| The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma S Hong, D Liu, S Luo, W Fang, J Zhan, S Fu, Y Zhang, X Wu, H Zhou, ... Nature communications 10 (1), 3108, 2019 | 87 | 2019 |
| Education and lung cancer: a Mendelian randomization study H Zhou, Y Zhang, J Liu, Y Yang, W Fang, S Hong, G Chen, S Zhao, ... International journal of epidemiology 48 (3), 743-750, 2019 | 83 | 2019 |
| First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy Y Zhou, Z Lin, X Zhang, C Chen, H Zhao, S Hong, L Zhang Journal for immunotherapy of cancer 7, 1-6, 2019 | 78 | 2019 |
| PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival W Fang, S Hong, N Chen, X He, J Zhan, T Qin, T Zhou, Z Hu, Y Ma, ... Oncotarget 6 (32), 33019, 2015 | 74 | 2015 |
Huaqiang ZhouSun Yat-sen University Cancer Center在 sysucc.org.cn 的电子邮件经过验证
Huaqiang ZhouSun Yat-sen University Cancer Center在 sysucc.org.cn 的电子邮件经过验证
Zhiyong GuoUniversity of Maryland在 umaryland.edu 的电子邮件经过验证